Latest News

  • INNOVATION

    25 Feb 2026

    Can AI Rethink How New Drugs Are Found?

  • PARTNERSHIPS

    24 Feb 2026

    Lilly Deepens AI Push in Obesity Drug Race

  • INVESTMENT

    23 Feb 2026

    Another Shot in the Obesity Gold Rush

  • MARKET TRENDS

    19 Feb 2026

    Precision Medicine Rises as Biomarkers Drive Change

Pfizer Steps Up Obesity Push With Metsera Deal

Pfizer corporate logo displayed outside office building

PARTNERSHIPS

17 Feb 2026

US drugmaker agrees multibillion-dollar acquisition to bolster metabolic pipeline and challenge leaders in weight-loss therapies

Pfizer research facility following Metsera acquisition in obesity drug strategy

PARTNERSHIPS

6 Jan 2026

Pfizer’s Metsera Deal Ignites a New Obesity Drug Arms Race

Pfizer’s Metsera buy sharpens its obesity strategy and signals a fiercer, faster fight for metabolic drug leadership

Ionis Pharmaceuticals sign representing liver-targeted drug research for MASH

RESEARCH

19 Dec 2025

Liver-First Drugs Redefine the Next Phase of the MASH Race

New 2025 data for Ionis ION224 highlight how liver-targeted drugs and GLP-1s may converge to reshape MASH care and deal-making

Business discussion reflecting FDA pilot voucher accelerating metabolic drug reviews

REGULATORY

18 Dec 2025

FDA Pilot Voucher Signals Faster Reviews for Metabolic Drugs

A new FDA pilot voucher could shrink review timelines for select obesity and diabetes drugs, stirring optimism and debate across the secto...

Colorful 3D rendering of mitochondria used in metabolic research

INNOVATION

17 Dec 2025

The Next Obesity Bet Lies Deep Inside Cells

As GLP-1 drugs dominate obesity care, a handful of biotechs are probing mitochondria, searching for new metabolic levers inside the cell

Zealand Pharma and OTR Therapeutics logos displayed for metabolic drug partnership

PARTNERSHIPS

16 Dec 2025

Zealand Pharma Expands Metabolic Ambitions With OTR Deal

Zealand Pharma and OTR Therapeutics strike a collaboration to develop oral metabolic drugs, widening the field beyond injectables

Prolynx logo displayed in teal circle on white background

INVESTMENT

15 Dec 2025

A $70M Bet on Longer-Lasting Metabolic Drugs

Prolynx lands fresh funding and a new CEO as investors shift focus to durability and adherence in next-generation obesity therapies

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.